Biomarkers Market growing at a CAGR of 11.2% from 2024 to 2033 | GE Healthcare, Siemens AG, Revvity, Inc., Agilent Technologies

The biomarkers market size was valued at $46.4 billion in 2023, and is estimated to reach $134.2 billion by 2033, growing at a CAGR of 11.2% from 2024 to 2033.

Biomarkers are measurable indicators that serve as objectifiable and quantifiable signs of biological processes, disease states, or responses to therapeutic interventions within an organism. They play a crucial role in the field of healthcare, such as in aiding in disease diagnosis, prognosis, and monitoring treatment efficacy. Moreover, biomarkers facilitate the development and evaluation of new drugs and therapies by enabling researchers to measure their impact on biological systems.

Request Sample of the Report -

https://www.alliedmarketresearch.com/press-release/biomarker-market.html

Factors that drive the growth of the biomarkers market size include a rise in geriatric population and surge in demand for companion diagnostics. Technological advancements in the field of biomarkers have emerged as a major driver for the biomarkers market share. According to the World Health Organization, it was estimated that by 2030, 1 in 6 people in the world are expected to be aged 60 years or over. As the geriatric population is on the rise globally, there is a heightened demand for effective diagnostic and prognostic tools to address the complex healthcare needs of this aging demographic.

Biomarkers Statistics:

Disease diagnosis segment is expected to register highest growth during the forecast period and is one of the major biomarkers market trends.

The assay development segment is expected to register the highest growth during the forecast period.

Asia-Pacific is expected to witness the highest CAGR during the forecast period.

The high development cost of biomarkers stands as a significant restraint for the growth of the biomarkers market.

Purchase the Report for Key Insights:

https://www.alliedmarketresearch.com/purchase-enquiry/87

Recent Developments in Biomarkers Industry:
In February 2024, Abbott Laboratories and Fujirebio announced a partnership to develop a research use only (RUO) neurofilament-light chain (Nf-L) neurology biomarker assay for use on Abbott's Alinity i.
In January 2024, Merck KGaA announced that it entered into a collaboration with Quibim, the global company transforming imaging data into actionable predictions of cancer progression and treatment response. The two companies explore how to harness the potential of biomarkers and radiomics to predict a cancer patient's response to immunotherapy and predict cancer patient outcomes.
In December 2023, GE HealthCare announced it has the lead industrial role in the European consortium project Predictom, a pioneer venture to use real-world data (RWD) coupled with artificial intelligence (AI) screening to advance identification of those with early signs of Alzheimer's disease. The predictom project aims to develop a digital platform that is expected to aggregate participant RWD in different screening stages, including imaging, blood, cerebrospinal fluid, electrophysiological, and digital biomarkers.
Regional Analysis:
North America region generated the highest revenue in 2022, owing to the strong presence of key players, well-developed healthcare infrastructure, and rise in geriatric population. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period, owing to a rise in prevalence of chronic diseases and surge in research initiatives by companies in the region.

Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/87

Market Segmentation -

The biomarkers market can be segmented based on various criteria, including:

Type of Biomarker:

Protein Biomarkers
Genetic Biomarkers (DNA, RNA, microRNA)
Metabolic Biomarkers
Imaging Biomarkers
Cellular Biomarkers
Other Biomarkers (e.g., epigenetic biomarkers, circulating tumor cells)

Application:

Disease Diagnosis (e.g., cancer, cardiovascular diseases, neurological disorders)
Drug Discovery and Development
Personalized Medicine
Risk Assessment and Prediction
Prognostic and Predictive Biomarkers
Therapeutic Monitoring
Other Applications (e.g., environmental monitoring, agriculture)

End User:

Hospitals and Clinics
Diagnostic Laboratories
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Contract Research Organizations (CROs)
Other End Users

Technology:

Immunoassays (ELISA, Western blotting, multiplex assays)
Molecular Assays (PCR, next-generation sequencing)
Imaging Technologies (PET, MRI, CT)
Mass Spectrometry
Flow Cytometry
Other Technologies

Disease Area:

Oncology
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Autoimmune Disorders
Metabolic Disorders
Other Disease Areas

Geography:

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

Key Player Analysis:
F. Hoffmann-La Roche AG
Revvity, Inc.
Qiagen N.V
Thermo Fisher Scientific
Bio-Rad Laboratories, Inc.
Siemens AG
Merck KGaA
GE Healthcare
Agilent Technologies Inc.
Abbott Laboratories

Request Customization:

https://www.alliedmarketresearch.com/request-for-customization/87

Contact Data:

David Correa,
1209 Orange Street, Corporation Trust Center, Wilmington, New Castle, Delaware 19801 USA.
Toll Free: +1-800-792-5285| Int'l: +1-503-894-6022
UK: +44-845-528-1300| Hong Kong: +852-301-84916
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.